Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

March 28, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Covid19
Interventions
DRUG

Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases

Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.

Trial Locations (1)

11795

Helwan University, Cairo

All Listed Sponsors
collaborator

Ain Shams University

OTHER

collaborator

Fayoum University

OTHER

collaborator

Assiut University

OTHER

collaborator

Tanta University

OTHER

collaborator

National Institute of Infectious Diseases, Tokyo, Japan

UNKNOWN

lead

Helwan University

OTHER

NCT04847661 - Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial | Biotech Hunter | Biotech Hunter